Market capitalization | $39.96b |
Enterprise Value | $36.29b |
P/E (TTM) P/E ratio | 9.77 |
EV/FCF (TTM) EV/FCF | 70.39 |
EV/Sales (TTM) EV/Sales | 6.18 |
P/S ratio (TTM) P/S ratio | 6.81 |
P/B ratio (TTM) P/B ratio | 4.19 |
Revenue growth (TTM) Revenue growth | 0.92% |
Revenue (TTM) Revenue | $5.87b |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
33 Analysts have issued a Edwards Lifesciences forecast:
33 Analysts have issued a Edwards Lifesciences forecast:
Sep '24 |
+/-
%
|
||
Revenue | 5,873 5,873 |
1%
1%
|
|
Gross Profit | 4,544 4,544 |
2%
2%
|
|
EBITDA | 1,748 1,748 |
4%
4%
|
EBIT (Operating Income) EBIT | 1,599 1,599 |
4%
4%
|
Net Profit | 4,159 4,159 |
191%
191%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into three areas: Transcatheter Heart Valves, Surgical Structural Heart and Critical Care. The Transcatheter Heart Valves portfolio includes technologies designed to treat heart valve disease using catheter-based approaches as opposed to open surgical techniques. Its portfolio includes technologies designed for nonsurgical replacement of heart valves. The Surgical Structural Heart portfolio includes tissue heart valves and heart valve repair products for the surgical replacement or repair of a patient's heart valve. The Critical Care portfolio products through hemodynamic monitoring system measures a patient's heart function and fluid status in surgical and intensive care settings. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.
Head office | United States |
CEO | Bernard Zovighian |
Employees | 19,800 |
Founded | 1958 |
Website | www.edwards.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.